Log in

NASDAQ:ARAYAccuray Stock Price, Forecast & News

$2.10
+0.01 (+0.48 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.03
Now: $2.10
$2.12
50-Day Range
$1.70
MA: $2.01
$2.40
52-Week Range
$1.33
Now: $2.10
$4.68
Volume416,905 shs
Average Volume517,736 shs
Market Capitalization$190.09 million
P/E Ratio105.05
Dividend YieldN/A
Beta2.03
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. The CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables the delivery of precise, high dose radiation while patients breathe normally. It also offers the TomoTherapy System, which consists of an integrated and versatile radiation therapy system used for the treatment of a range of cancer types. The company markets its products in the United States directly, as well as through a sales agent and group purchasing organizations; and directly and through distributors and sales agents in Europe, Japan and other countries of Asia, South America, and internationally to hospitals and stand-alone treatment facilities. Accuray Incorporated was incorporated in 1990 and is headquartered in Sunnyvale, California.
Read More
Accuray logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.48 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:ARAY
CUSIP00439710
Phone408-716-4600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$418.79 million
Book Value$0.66 per share

Profitability

Net Income$-16,430,000.00

Miscellaneous

Employees998
Market Cap$190.09 million
Next Earnings Date8/20/2020 (Estimated)
OptionableOptionable

Receive ARAY News and Ratings via Email

Sign-up to receive the latest news and ratings for ARAY and its competitors with MarketBeat's FREE daily newsletter.

Accuray (NASDAQ:ARAY) Frequently Asked Questions

How has Accuray's stock been impacted by COVID-19 (Coronavirus)?

Accuray's stock was trading at $2.27 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ARAY stock has decreased by 7.5% and is now trading at $2.10. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Accuray?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accuray in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Accuray.

When is Accuray's next earnings date?

Accuray is scheduled to release its next quarterly earnings announcement on Thursday, August 20th 2020. View our earnings forecast for Accuray.

How were Accuray's earnings last quarter?

Accuray Incorporated (NASDAQ:ARAY) posted its quarterly earnings data on Tuesday, April, 28th. The medical equipment provider reported $0.03 EPS for the quarter, beating the Zacks' consensus estimate of ($0.04) by $0.07. The medical equipment provider had revenue of $99.55 million for the quarter, compared to analysts' expectations of $96.46 million. Accuray had a net margin of 0.64% and a negative return on equity of 14.83%. View Accuray's earnings history.

What price target have analysts set for ARAY?

2 equities research analysts have issued twelve-month price targets for Accuray's stock. Their forecasts range from $4.00 to $9.50. On average, they expect Accuray's share price to reach $6.75 in the next twelve months. This suggests a possible upside of 221.4% from the stock's current price. View analysts' price targets for Accuray.

Has Accuray been receiving favorable news coverage?

Media coverage about ARAY stock has trended very negative recently, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Accuray earned a daily sentiment score of -3.4 on InfoTrie's scale. They also gave news articles about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutAccuray.

Are investors shorting Accuray?

Accuray saw a increase in short interest in April. As of April 30th, there was short interest totaling 2,960,000 shares, an increase of 41.0% from the April 15th total of 2,100,000 shares. Based on an average daily volume of 667,800 shares, the days-to-cover ratio is currently 4.4 days. Approximately 3.4% of the company's stock are sold short. View Accuray's Current Options Chain.

Who are some of Accuray's key competitors?

What other stocks do shareholders of Accuray own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Accuray investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Activision Blizzard (ATVI), Intel (INTC), Tesla (TSLA), Corbus Pharmaceuticals (CRBP), Netflix (NFLX), Abeona Therapeutics (ABEO), Amarin (AMRN) and AVEO Pharmaceuticals (AVEO).

Who are Accuray's key executives?

Accuray's management team includes the following people:
  • Mr. Joshua H. Levine, Pres, CEO & Director (Age 61)
  • Mr. Andrew Kirkpatrick, Sr. VP & COO (Age 56)
  • Mr. Lionel Hadjadjeba, Sr. VP & Chief Customer Experience Officer (Age 60)
  • Mr. Shigeyuki Hamamatsu, Sr. VP & CFO (Age 46)
  • Mr. Patrick R. Spine, Sr. VP & Chief Admin. Officer

What is Accuray's stock symbol?

Accuray trades on the NASDAQ under the ticker symbol "ARAY."

Who are Accuray's major shareholders?

Accuray's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (7.07%), Primecap Management Co. CA (4.79%), Russell Investments Group Ltd. (3.93%), JPMorgan Chase & Co. (2.26%), State Street Corp (1.85%) and Geode Capital Management LLC (1.47%). Company insiders that own Accuray stock include Alaleh Nouri, Andrew J Kirkpatrick, Jesse Chew, Joseph E Whitters, Joshua Levine, Kevin Waters, Patrick Spine and Shigeyuki Hamamatsu. View institutional ownership trends for Accuray.

Which major investors are selling Accuray stock?

ARAY stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Two Sigma Investments LP, Primecap Management Co. CA, UBS Group AG, Squarepoint Ops LLC, Morgan Stanley, Spark Investment Management LLC, and Assenagon Asset Management S.A.. Company insiders that have sold Accuray company stock in the last year include Andrew J Kirkpatrick, Jesse Chew, Joshua Levine, and Shigeyuki Hamamatsu. View insider buying and selling activity for Accuray.

Which major investors are buying Accuray stock?

ARAY stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Voce Capital Management LLC, Wellington Management Group LLP, Cowen Prime Services LLC, GSA Capital Partners LLP, Russell Investments Group Ltd., Dupont Capital Management Corp, and Los Angeles Capital Management & Equity Research Inc.. Company insiders that have bought Accuray stock in the last two years include Joseph E Whitters, and Joshua Levine. View insider buying and selling activity for Accuray.

How do I buy shares of Accuray?

Shares of ARAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Accuray's stock price today?

One share of ARAY stock can currently be purchased for approximately $2.10.

How big of a company is Accuray?

Accuray has a market capitalization of $190.09 million and generates $418.79 million in revenue each year. The medical equipment provider earns $-16,430,000.00 in net income (profit) each year or ($0.15) on an earnings per share basis. Accuray employs 998 workers across the globe.

What is Accuray's official website?

The official website for Accuray is www.accuray.com.

How can I contact Accuray?

Accuray's mailing address is 1310 CHESAPEAKE TERRACE, SUNNYVALE CA, 94089. The medical equipment provider can be reached via phone at 408-716-4600 or via email at [email protected]

This page was last updated on 5/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.